Estimation of the number of blood donors during the COVID-19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
Estimation of the number of blood donors during the COVID-19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
复制标题
中国COVID-19潜伏期献血人数估算及输血传播防控措施分析
DOI：
10.1111/trf.15858
复制
发表时间：
2020-05-22
期刊：
影响因子：
2.9
通讯作者：
Wei, Yaming
中科院分区：
文献类型：
--
作者：
Yuan, Zhaohu;Chen, Dandan;Wei, Yaming
研究设计和方法在这项研究中，我们开发了一个预测模型来估计中国34个省级地区在COVID-19潜伏期内的献血者人数。我们的主要假设是，不同地区的所有年龄段的献血者都有稳定的献血意愿和相同的感染风险。结果首先，我们估计了2019年12月31日至2020年3月17日，湖北省武汉市和中国的COVID-19潜伏期内的献血者人数。其次，我们比较了中国所有省份在COVID-19潜伏期内的献血人数。此外，我们发现，如果所有的红细胞、血浆和冷沉淀都隔离储存到第14天，在献血者安全度过COVID-19潜伏期后，通过输血传播SARS-CoV-2的潜在风险至少降低了65.77%。结论随着COVID-19疫情的迅速蔓延，其传染性和病死率均呈现出惊人的高水平，尽管风险较低，但卫生部门仍应采取相应措施，确保临床血液安全。
BACKGROUND The aim of this study was to estimate the number of blood donors during the COVID-19 incubation period across China.STUDY DESIGN AND METHODS In this study, we developed a predictive model to estimate the number of blood donors during the COVID-19 incubation period among 34 provincial regions in China. Our main assumption was that blood donors of all ages in different regions have a stable blood donation intention and the same infection risk.RESULTS First, we estimated the number of blood donors during the COVID-19 incubation period in Wuhan city, Hubei Province, and China, from December 31, 2019 to March 17, 2020. Second, we compared the number of blood donors during the COVID-19 incubation period in all provinces across China. In addition, we found that if all RBCs, plasma, and cryoprecipitation were stored in isolation until the 14th day, the potential risk of SARS-CoV-2 transmission through blood transfusion was reduced by at least 65.77% after the blood donor safely passed the COVID-19 incubation period. Moreover, if the detection of SARS-CoV-2 RNA was carried out on all platelets, the potential risk would be reduced by 77.48%.CONCLUSIONS Although the risk is low, with the rapid spread of the COVID-19 and the appearance of alarmingly high infectivity and a high fatality rate, appropriate measures should be taken by health departments to ensure the safety of clinical blood.